Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Ebiomedicine|December 3, 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialPeter Bergman, Ola Blennow, Lotta Hansson, et al.
Leukemia|August 30, 2019
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysisStefan Knop, Monika Engelhardt, Peter Liebisch, et al.
Med (New York, N.Y.)|January 25, 2022
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individualsKatie Healy, Elisa Pin, Puran Chen, et al.
Leukemia|November 20, 2024
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT studyGuillermo Ortí, Christophe Peczynski, William Boreland, et al.
Leukemia|June 3, 2021
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective surveyPer Ljungman, Rafael de la Camara, Malgorzata Mikulska, et al.
Lancet (London, England)|February 15, 2026
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 studyM Lia Palomba, Stephen J Schuster, Reem Karmali, et al.
The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.
Nature Medicine|June 3, 2024
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Saurabh Dahiya, M Lia Palomba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2024
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell TransplantationMagnus Tobiasson, Tatjana Pandzic, Johanna Illman, et al.
Pageof 13